Irritable bowel syndrome and chronic constipation: Emerging drugs, devices, and surgical treatments

Current Gastroenterology Reports

Volumn 8, Issue 4, 2006, Pages 282-290

  Harris, Lucinda A ^b   Hansel, Stephanie ^b   DiBaise, John ^b   Crowell, Michael D ^a  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

17 METHYLNALTREXONE; ALVIMOPAN; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; ASIMADOLINE; BENZODIAZEPINE DERIVATIVE; BETHANECHOL; BIFIDOBACTERIUM LONGUM INFANTIS EXTRACT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CILANSETRON; COLCHICINE; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; DEXTOFISOPAM; DULOXETINE; LUBIPROSTONE; MISOPROSTOL; MOSAPRIDE CITRATE; NEOMYCIN; PROBIOTIC AGENT; RENZAPRIDE; RIFAXIMIN; SACCHAROMYCES BOULARDII EXTRACT; SODIUM DIHYDROGEN PHOSPHATE; TACHYKININ RECEPTOR ANTAGONIST; TALNETANT; TEGASEROD; TOFISOPAM; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VISICOL;

ABDOMINAL PAIN; ABDOMINAL SURGERY; ACUPUNCTURE; ALOPECIA; APLASTIC ANEMIA; BEHAVIOR THERAPY; BIFIDOBACTERIUM LONGUM INFANTIS; CLINICAL TRIAL; COGNITIVE THERAPY; COLON RESECTION; CONSTIPATION; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; ECG ABNORMALITY; ENVIRONMENTAL FACTOR; EPIGASTRIC DISCOMFORT; GASTROINTESTINAL MOTILITY DISORDER; GENETIC PREDISPOSITION; HEADACHE; HEALTH CARE COST; HEART ARRHYTHMIA; HUMAN; HYPERSALIVATION; HYPNOSIS; ILEOSTOMY; IRRITABLE COLON; ISCHEMIC COLITIS; KIDNEY DISEASE; MYENTERIC PLEXUS; NAUSEA; NEUROMUSCULAR DISEASE; NEUTROPENIA; PATHOPHYSIOLOGY; PREVALENCE; QUALITY OF LIFE; REVIEW; SACCHAROMYCES BOULARDII; SPONTANEOUS ABORTION; SYSTEMATIC REVIEW; VOMITING;

CONSTIPATION; ELECTRIC STIMULATION THERAPY; GASTROINTESTINAL AGENTS; HUMANS; ILEOSTOMY; IRRITABLE BOWEL SYNDROME; PREVALENCE; TREATMENT OUTCOME; WORLD HEALTH;

EID: 33746904663     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-006-0048-y     Document Type: Review

References (73)

1. American College of Gastroenterology Functional Gastrointestinal Disorders Task Force: Evidence-based position statement on the management of irritable bowel syndrome in North America. Am J Gastroenterol. 2002, 97(11 Suppl):S1-S5.
2. Harris L, Chang L. The functional bowel spectrum. In Textbook of Fibromyalgia and Other Non-Neuropathic Pain Syndromes. Edited by Wallace DJ, Clauw DJ. Philadelphia: Lippincott, Williams & Wilkins; 2005.
3. Tillisch K, Labus J, Naliboff B, et al.: Characterization of the alternating bowel habit subtype in patients with irritable bowel syndrome. Am J Gastroenterol 2005, 100:896-904.
4. Tillisch K, Chang L: Diagnosis and treatment of irritable bowel syndrome: State of the art. Current Gastroenterol Rep 2005, 7:249-256.
5. Drossman DA, Whitehead WE, Camilleri M: Irritable bowel syndrome: a technical review for practice guideline development. Gastroenterology 1997, 112:2120-2137.
6. Martin R, Barron JJ, Zacker C: Irritable bowel syndrome: toward a cost-effective management approach. Am J Manag Care 2001, 7:S268-S275.
7. Drossman DA, Camilleri M, Mayer EA, Whitehead WE: AGA technical review on irritable bowel syndrome. Gastroenterology 2002, 123:2108-2131.
8. Cole JA, Yeaw JM, Cutone JA, et al.: The incidence of abdominal and pelvic surgery among patients with irritable bowel syndrome. Dig Dis Sci 2005, 50:2268-2275.
9. Chang L, Heitkemper MM: Gender differences in irritable bowel syndrome. Gastroenterology 2002, 123:1686-1701.
10. Mertz H, Naliboff B, Munakata J, et al.: Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology. 1995, 109:40-52. Erratum in Gastroenterology 1997, 113:1054.
11. Dinan T, Quigley E, Ahmed SM, et al.: Hypothalamic-pituitary-gut axis dysregulation irritable bowel syndrome: plasma cytokines as a potential biomarker? Gastroenterology 2006, 130:304-311.
12. Chang L: Neuroendocrine and neuroimmune markers in IBS: pathophysiological role or epiphenomenon? Gastroenterology 2006, 130:596-600.
13. Camilleri M, Talley NJ: Pathophysiology as a basis for understanding symptom complexes and therapeutic targets. Neurogastroenterol Motil 2004, 16:135-142.
14. Brandt LJ, Bjorkman D, Fennerty MB, et al.: Systematic review on the management of irritable bowel syndrome in North America. Am J Gastroenterol 2002, 97:S7-S26.
15. Spiegel BM, DeRosa VP, Gralnek IM, et al.: Testing for celiac sprue in irritable bowel syndrome with predominant diarrhea: a cost-effectiveness analysis. Gastroenterology 2004, 126:1721-1732.
16. Camilleri M: Treating irritable bowel syndrome: overview, perspective and future therapies. Br J Pharmacology 2004, 141:1237-1248.
17. Chial HJ, Camilleri M, Burton D, et al.: Selective effects of serotonergic psychoactive agents on gastrointestinal functions in health. Am J Physiol 2003a, 84:G130-G137.
18. Bradette M, Moennikes H, Carter F, et al.: Cilansetron in irritable bowel syndrome with diarrhea predominance (IBS-D): efficacy and safety in a 6 month global study. Gastroenterology 2004, 126:A42.
19. Coremans G, Clouse RE, Carter F, et al.: Cilansetron, a novel 5-HT3 antagonist, demonstrated efficacy in males with irritable bowel syndrome with diarrhea-predominance (IBS-D). Gastroenterology 2004, 126:A643.
20. Harris L, Kuo B, Carter F, et al.: Quality of life in irritable bowel syndrome with diarrhea predominance (IBS-D) patients decreases after blinded withdrawal of cilansetron treatment. Gastroenterology 2005, 128 (Suppl 2):A458.
21. Chey WD, Cash BD: Cilansetron: a new serotonergic agent for the irritable bowel syndrome with diarrhea. Expert Opin Invest Drugs 2005, 14:185-193.
22. Meyers NL, Palmer RMJ, George A: Efficacy and safety of renzapride in patients with constipation-predominant IBS: a phase IIb study in the UK primary healthcare setting. Gastroenterology 2004, 126:A640.
23. Camilleri M, McKinzie S, Fox J, et al.: Renzapride accelerates colonic transit and improves bowel function in constipation predominant irritable bowel syndrome (C-IBS). Gastroenterology 2004, 126:A642.
24. Lubiprostone: RU 0211, SPI 0211. Drugs R D 2005, 6:245-248.
25. Osipenko MF, Khramov IA, Makarova TA, Vdovenko EG: Role of grandaxin in the treatment of functional gastrointestinal diseases. Ter Arkh 2000, 72:23-27.
26. Horvath EJ, Horvath K, Hamori T, et al.: Anxiolytic 2,3, benzodiazepines, their specific binding to the basal ganglia. Prog Neurobiol 2000, 60:309-342.
27. Leventer S, Raudibaugh K, Frissora C, et al.: The safety and efficacy of dextofisopam is patients with diarrhea-predominant or alternating irritable bowel syndrome. Gastroenterology 2005, 128(Suppl 2):A94.
28. Holzer P, Holzer-Petsche U: Tachykinins in the gut. Part II. Roles in neural excitation, secretion and inflammation. Pharmacol Ther 1997, 73:219-263.
29. Evangelista S: Talnetant GlaxoSmithKline. Curr Opin Investig Drugs 2005, 6:717-721.
30. Sagami Y, Shimada Y, Tayama J, et al.: Effect of a corticotrophin releasing hormone receptor antagonist on colonic sensory and motor function in patients with irritable bowel syndrome. Gut 2004, 53:58-64.
31. Ozake N, Sengupta JN, Gebhart GF: Differential effects of mu-, delta and kappa-opioid receptor agonists on the mechanosensitive gastric vagal afferent fibers in the rat. J Neurophysiol 2000, 83:2209-2216.
32. Delgado-Aros S, Chial HJ, Camilleri M, et al.: Effects of a kappa-opioid agonist, asimadoline, on satiation and GI motor and sensory functions in humans. Am J Physiol Gastrointest Liver Physiol 2003 284:G558-G566.
33. Delvaux M, Beck A, Jacob J, et al.: Effect of asimadoline, a kappa opioid agonist, on pain induced by colonic distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2004, 20:237-246.
34. Pimentel, M, Chow EJ, Lin HC: Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000, 95:3503-3506.
35. Pimentel M, Chow EJ, Lin HC: Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome, a double-blind randomized, placebo-controlled study. Am J Gastroenterol 2003, 98:412-419.
36. Pimentel M, Park S, Kong Y, et al.: Rifaximin, a non-absorbable antibiotic, improves the symptoms of irritable bowel syndrome: a double-blind randomized controlled study. Am J Gastroenterol 2005, 100:A882.
37. O'Mahoney L, McCarthy J, Kelly P, et al.: Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005, 128:541-551.
38. Kim HJ, Camilleri M, McKinzie S, et al.: A randomized controlled trial of a probiotic: VSL#3 on gut transit and symptoms in diarrhea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2003, 17:894-904.
39. Drossman DA, Corazziari E, Talley NJ, et al.: Rome II. The Functional Gastrointestinal Disorders. Diagnosis, Pathophysiology and Treatment: A Multinational Consensus, edn 2. McLean, VA: Degnon Associates; 2000:351-432.
40. American College of Gastroenterology Chronic Constipation Task Force. An evidence-based approach to the management of chronic constipation in North America. Am J Gastroenterol 2005, 100:S1-S4.
41. Brandt LJ, Prather CM, Quigley EM, et al.: Systematic review on the management of chronic constipation in North America. Am J Gastroenterol. 2005, 100(Suppl 1):S5-S22.
42. Irvine EJ, Ferrazzi S, Pare P, et al.: Health related quality of life in functional GI disorders: Focus on constipation and resource utilization. Am J Gastroenterol 2002, 97:1986-1993.
43. Higgins PD, Johanson JF: Epidemiology of constipation in North America: a systematic review. Am J Gastroenterol 2004, 99:750-759.
44. Yu CS, Kim HC, Hong HK, et al.: Evaluation of myenteric ganglion cells and interstitial cells Cajal in patients with chronic idiopathic constipation. Int J Colorectal Dis 2002, 17:253-258.
45. Bjornsson ES, Chey WD, Hooper F, et al.: Impaired gastrocolonic response and peristaltic reflex in slow-transit constipation: role of 5-HT(3) pathways. Am J Physiol Gastrointest Liver Physiol 2002, 283:G400-G407.
46. Lyford GL. He CL., Soffer E, et al.: Pan-colonic decrease in interstitial cells of Cajal in patients with slow transit constipation. Gut 2002, 51:496-501.
47. Crowell MD. Pathogenesis of slow transit and pelvic floor dysfunction: from bench to bedside. Rev Gastroenterol Disord 2004, 4(Suppl 2):S17-S27.
48. Prather C: Subtypes of constipation: sorting out the confusion. Rev Gastroenterol Disord 2004, 4(Suppl 2): S11-S16.
49. Medoff J, Katz S, Malik P, et al.: Open-label, dose-ranging pilot study of 4 weeks of low-dose therapy with sodium phosphate tablets in chronically constipated adults. Clin Ther 2004, 26:1479-1491.
50. Markowitz GS, Stokes MB, Radhakrishnan J, et al.: Acute phosphate nephropathy following oral sodium phosphate bowel purgative: an underrecognized cause of chronic renal failure. J Am Soc Nephrol 2005, 16:3389-3396.
51. Dipalma J: Current treatment options for chronic constipation. Rev Gastroenterol Disord 2004, 4(Suppl 2): S34-S42.
52. Roarty TP, Weber F, Soykan I, McCallum RW: Misoprostol in the treatment of chronic refractory constipation: results of a long-term open label trial. Aliment Pharmacol Ther 1997, 11:1059-1066.
53. Verne GN, Davis RH, Robinson ME, et al.: Treatment of chronic constipation with colchicine: Randomized, double-blind, placebo-controlled, crossover trial. Am J Gastroenterol 2003, 98:1112-1116.
54. Prather CM, Camilleri M, Zinsmeister AR, et al.: Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology 2000, 118:463-468.
55. Degen L, Matzinger D, Merz M, et al.: Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. Aliment Pharmacol Ther 2001, 15:1745-1751.
56. Ramkumar D, Rao SS: Efficacy and safety of traditional medical therapies for chronic constipation: systematic review. Am J Gastroenterol 2005, 100:936-971.
57. Johanson JF, Wald A, Tougas GC, et al.: Effect of tegaserod in chronic constipation: a randomized, double-blind, controlled trial. Clin Gastroenterol Hepatol. 2004, 2:796-805.
58. Kamm MA, Muller-Lissner S, Talley NJ, et al.: Tegaserod for the treatment of chronic constipation: a randomized, double-blind, placebo-controlled multinational study. Am J Gastroenterol 2005, 100:362-372. Erratum in Am J Gastroenterol. 2005, 100:735.
59. DiBaise JK: Tegaserod-associated ischemic colitis. Pharmacotherapy. 2005, 25:620-625.
60. Liu Z, Sakakibara R, Odaka T, et al.: Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in parkinsonian patients. Mov Disord 2005, 20:680-686.
61. Camilleri M, McKinzie S, Fox J, et al.: Effect of renzapride on transit in constipation-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol 2004, 2:895-904.
62. Johanson JF, Gargano MA, Holland PC, et al.: Phase III, randomized withdrawal study of RU-0211, a novel chloride channel activator for the treatment of constipation [abstract 749]. Gastroenterology 2004, 126(Suppl 2):A100.
63. Johanson JF, Gargano M, Holland PC, et al.: Phase III efficacy and safety of RU-0211, a novel chloride channel activator, for the treatment of constipation [abstract 372]. Gastroenterology 2003, 124(Suppl 1):A48.
64. Kurz A, Sessler DI: Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs 2003, 63:649-671.
65. Brown DR Goldberg LI: The use of quaternary narcotic antagonists in opiate research. Neuropharmacology 1985, 24:181-191.
66. Yuan CS, Wei G, Foss JF, et al.: Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: a double-blind randomized placebo-controlled trial. J Pharmacol Exp Ther 2002, 300:118-123.
67. Russell J, Bass P, Goldberg LI, et al.: Antagonism of gut, but not central effects of morphine with quaternary narcotic antagonists. Eur J Pharmacol 1982, 78:255-261.
68. Camilleri M: Alvimopan, a selective peripherally acting mu-opioid antagonist. Neurogastroenterol Motil 2005, 17(2):157-165.
69. Paulson DM, Kennedy DT, Donovick RA, et al.: Alvimopan: an oral, peripherally acting, mu-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction - a 21-day treatment randomized clinical trial. J Pain 2005, 6:184-192.
70. Barucha AE: Treatment of severe and intractable constipation. Curr Treat Options Gastroenterol 2004, 7:291-298.
71. Kenefick NJ, Nicholls RJ, Cohen RG, Kamm MA: Permanent sacral nerve stimulation for treatment of idiopathic constipation. Br J Surg 2002, 89:882-888.
72. Gomez Garcia I, Fernandez Fernandez E, Sanz Mayayo E, et al.: Sacral root neuromodulation. Experience in our site: 1998-2003, concerning 18 definite neuromodulation implants. Acta Urol Esp 2004, 28:732-742.
73. Fajardo NR, Pasiliano R-V, Duncan R, et al.: The effect of neuromuscular stimulation of the abdominal muscles on defecation after spinal chord injury [SCI]. Gastroenterology 2001, 120:A109.